Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023

Author:

Hynds Robert E.1ORCID,Magin Chelsea M.234ORCID,Ikonomou Laertis56ORCID,Aschner Yael2ORCID,Beers Michael F.7ORCID,Burgess Janette K.8ORCID,Heise Rebecca L.9ORCID,Hume Patrick S.10ORCID,Krasnodembskaya Anna D.11ORCID,Mei Shirley H. J12ORCID,Misharin Alexander V.13,Park Jin-Ah14ORCID,Reynolds Susan D.15,Tschumperlin Daniel J.16ORCID,Tanneberger Alicia E.3,Vaidyanathan Sriram17,Waters Christopher M.18ORCID,Zettler Patricia J.19,Weiss Daniel J.20,Ryan Amy L.21ORCID

Affiliation:

1. Epithelial Cell Biology in ENT Research Group, Developmental Biology and Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom

2. Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

3. Department of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

4. Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

5. Department of Oral Biology, University at Buffalo, State University of New York, Buffalo, New York, United States

6. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, United States

7. Pulmonary, Allergy, and Critical Care Division, Department of Medicine and PENN-CHOP Lung Biology Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

8. Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands

9. Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia, United States

10. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States

11. Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom

12. Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

13. Division of Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States

14. Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, United States

15. Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States

16. Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States

17. Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, United States

18. Department of Physiology and Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States

19. Moritz College of Law, Drug Enforcement and Policy Center, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States

20. Department of Medicine, University of Vermont, Burlington, Vermont, United States

21. Department of Anatomy and Cell Biology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States

Abstract

Repair and regeneration of a diseased lung using stem cells or bioengineered tissues is an exciting therapeutic approach for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence from preclinical models suggests that mesenchymal stromal cells, which are not normally resident in the lung, can be used to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating the use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those involving stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in our understanding of the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise during lung development and participate in normal and pathological remodeling after lung injury. For the 2023 Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference, scientific symposia were chosen to reflect the most cutting-edge advances in these fields. Sessions focused on the integration of “omics” technologies with function, the influence of immune cells on regeneration, and the role of the extracellular matrix in regeneration. The necessity for basic science studies to enhance fundamental understanding of lung regeneration and to design innovative translational studies was reinforced throughout the conference.

Funder

HHS | NIH | National Heart, Lung, and Blood Institute

National Science Foundation

Publisher

American Physiological Society

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3